How is ceftobiprole used in Canada: the CLEAR study final results

References

• Zhanel GG, Lam A, Schweizer F, et al. Ceftobiprole: a review of a broad spectrum and anti-MRSA cephalosporin. Amer J Clin Dermatol. 2008;9(4):245–254. doi: 10.2165/00128071-200809040-00004
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Voth D, Nichol K, et al. Pharmacodynamics activity of ceftobiprole compared to vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother. 2009;64(2):364–369. doi: 10.1093/jac/dkp176
   PubMed Web of Science ®Google Scholar
• Salem AH, Zhanel GG, Ibrahim SA, et al. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014;41(6):437–443. doi: 10.1111/1440-1681.12195
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Weite T, File TM, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39(3):240–246. doi: 10.1016/j.ijantimicag.2011.11.005
   PubMed Web of Science ®Google Scholar
• Awad S, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59(1):51–61. doi: 10.1093/cid/ciu219
   PubMed Web of Science ®Google Scholar
• Rotstein C, Lynch JP, Zhanel GG. Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials. Exp Rev Antiinfect Ther. 2023 Oct;9(11):1–3. doi: 10.1080/14787210.2023.2268287
   Google Scholar
• Crapis M, Venturini S, Siega PD, et al. Ceftobiprole and pneumonia in adults admitted to emergency department is it time to assess the new therapeutic algorithm? Journal Of Chemotherapy. 2021;33(3):174–179. doi: 10.1080/1120009X.2020.1821486
   PubMed Web of Science ®Google Scholar
• Scheeren TWL, Weite T, Saulay M, et al. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials. BMC Infect Dis. 2019;19(1):195–201. doi: 10.1186/s12879-019-3820-y
   PubMedGoogle Scholar
• Hsu WH, Hsu CK, Lai CC, et al. Ceftobiprole medocaril for the treatment of pneumonia. Expert Rev Anti Infect Ther. 2023;21(6):551–563. doi: 10.1080/14787210.2023.2202851
   PubMed Web of Science ®Google Scholar
• Overcash JC, Kim C, Keech R, et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized double blind trial (TARGET). Clin Infect Dis. 2020;73(7):1507–1517. doi: 10.1093/cid/ciaa974
   Web of Science ®Google Scholar
• Leventogiannis K, Mouktaroudi M, Giamarellos-Bourboulis EJ, et al. Clinical evidence, supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections. Opin Infect Dis. 2023;36(2):89–94. doi: 10.1097/QCO.0000000000000900
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Mazza MC, et al. Real-life experience with ceftobiprole in a tertiary-care hospital. J Glob Antimicrob Resist. 2020;22:386–390. doi: 10.1016/j.jgar.2020.03.010
   PubMed Web of Science ®Google Scholar
• Bellut H, Arrayago M, Amara M, et al. Real life ceftobiprole use for severe infections in a French intensive care unit. Infect Dis Now. 2023 Sep;27(1):104790. doi: 10.1016/j.idnow.2023.104790
   Google Scholar
• Hidalgo-Tenorio C, Pitto-Robles I, Arnés García D, et al. Cefto real-life study: real world data on the use of ceftobiprole in a multi center, Spanish cohort. Antibiotics (Basel). 2023;12(7):1218. doi: 10.3390/antibiotics12071218
   PubMed Web of Science ®Google Scholar
• Zampino R, Gallo R, Salemme A, et al. Clinical results with the use of ceftaroline and ceftobiprole: real-life experience in a tertiary care hospital. Int J Antimicrob Agents. 2023;62(2):106883. doi: 10.1016/j.ijantimicag.2023.106883
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Corcione S, et al. CEFTO-CURE study: CEFTObiprole clinical use in real-lifE – a multi-centre experience in Italy. Int J Antimicrob Agent. 2023;62(1):1–10. doi: 10.1016/j.ijantimicag.2023.106817
   Web of Science ®Google Scholar
• Macdonald A, Dow G. Ceftobiprole: first reported experience in osteomyelitis. Can J Infect Dis Med Microbiol. 2010;21(3):138–140. doi: 10.1155/2010/296760
   PubMed Web of Science ®Google Scholar
• Tascini C, Attanasio V, Ripa M, et al. Ceftobiprole for the treatment of infective endocarditis: a case series. J Glob Antimicrob Resist. 2020;20:56–59. doi: 10.1016/j.jgar.2019.07.020
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Sniezek G, Schweizer F, et al. A review of ceftaroline: a novel broad-spectrum cephalosporin with activity against MRSA. Drugs. 2009;69(7):809–831. doi: 10.2165/00003495-200969070-00003
   PubMed Web of Science ®Google Scholar
• Holland TL, Cosgrove SE, Doernberg SB, et al. Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia. N Engl J Med. 2023;389(15):1390–1401. doi: 10.1056/NEJMoa2300220
   PubMed Web of Science ®Google Scholar
• Fernandez J, Abbanat D, Shang W, et al. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56(3):1476–1484. doi: 10.1128/AAC.06057-11
   PubMed Web of Science ®Google Scholar
• Mahmoud E, Al Mansour S, Bosaeed M, et al. Ceftobiprole for treatment of MRSA blood stream infection: a case series. Infect Drug Resist. 2020;13:2667–2672. doi: 10.2147/IDR.S254395
   PubMed Web of Science ®Google Scholar
• Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus dAPTOMYCin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, phase III trial. Future Microbiol. 2020;15(1):35–48. doi: 10.2217/fmb-2019-0332
   PubMed Web of Science ®Google Scholar
• Soriano A, Morata L. Ceftobripole: experience in staphylococcal bacteremia. Rev Esp Quimioter. 2019;32 (Suppl 3):24–28. doi: 10.1111/1469-0691.12144
   PubMed Web of Science ®Google Scholar
• Barber KE, Werth BJ, Ireland CE, et al. Potent synergy of ceftobiprole plus daptomycin against multiple strains of staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother. 2014;69(11):3006–3010. doi: 10.1093/jac/dku236
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Kosar J, Baxter M, et al. Real life experience with ceftobiprole in Canada: results from the CLEAR (Canadian leadership on antimicrobial real-life usage) registry. J Glob Antimicrob Resis. 2021;24:335–339. doi: 10.1016/j.jgar.2021.01.014
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Adam HJ, Baxter MR, et al. 42936 pathogens from canadian hospitals: 10 years of results (2007-2016) from the CANWARD surveillance study. 2007-2016. J Antimicrob Chemother. 2019;74(Supplement 4):5–21. doi: 10.1093/jac/dkz283
   Google Scholar
• Lagace-Wiens PRS, Adam HJ, Poutanen S, et al. Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results on the CANWARD study 2007-2016. J Antimicrob Chemother. 2019;74(Supplement 4):22–31. doi: 10.1093/jac/dkz284
   PubMedGoogle Scholar
• Nichol KA, Adam HJ, Golding GR, et al. Characterization of MRSA in Canada from 2007-2016. J Antimicrob Chemother. 2019;74(Supplement 4):55–63. doi: 10.1093/jac/dkz288
   Google Scholar
• Lynch JP, Zhanel GG. Escalation of antimicrobial resistance among MRSA part 1: focus on global spread. Exp Rev Antiinfective Ther. 2022 Dec;12(2):1–15. doi: 10.1080/14787210.2023.2154653
   Google Scholar
• Lynch JP, Zhanel GG. Zhanel GG escalation of antimicrobial resistance among MRSA part 2: focus on treatment. Exp Rev Antiinfective Ther. 2022 Dec;21(2):1–12. doi: 10.1080/14787210.2023.2154654
   PubMed Web of Science ®Google Scholar
• Lynch JP, Clark NM, Zhanel GG. Escalating antimicrobial resistance among enterobacteriaceae: focus on carbapenemases. Exp Opin Pharmacother. 2021;22(11):1455–1473. doi: 10.1080/14656566.2021.1904891
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multi-drug resistant gram-negative bacilli. Drugs. 2019;79(3):271–289. doi: 10.1007/s40265-019-1055-2
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159–177. doi: 10.1007/s40265-013-0013-7
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78(1):65–98. doi: 10.1007/s40265-017-0851-9
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline: a novel fluorocycline antibacterial agents. Drugs. 2016;76(5):567–588. doi: 10.1007/s40265-016-0545-8
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Exp Rev Antiinfect Ther. 2012;10(4):459–473. doi: 10.1586/eri.12.25
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Baxter M, Wong M, et al. Real life experience with IV fosfomycin in Canada: results from the CLEAR (Canadian leadership on antimicrobial real-life usage) registry. J Glob Antimicrob Resis. 2023;3:171–176. doi: 10.1016/j.jgar.2023.03.010
   Google Scholar
• Zhanel GG, Dhami R, Baxter M, et al. Real life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian leadership on antimicrobial real-life usage) registry. J Glob Antimicrob Resis. 2021 Jun;25:346–350. doi: 10.1016/j.jgar.2021.03.025
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010
   PubMed Web of Science ®Google Scholar
• Bavaro DF, Belati A, Diella L, et al. Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study. J Antimicrob Chemother. 2023;78(9):2175–2184. doi: 10.1093/jac/dkad215
   PubMed Web of Science ®Google Scholar
• Roberts JA, Croom K, Adamakoh N. Continuous infusion of beta-lactam antibiotics: narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy. Exp Rev Antiinfect Ther. 2023;21(4):375–385. doi: 10.1080/14787210.2023.2184347
   PubMed Web of Science ®Google Scholar
• Gatti M, Pea F. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-gram-negative infections with novel beta-lactams. Exp Rev Antiinfect Ther. 2023;21(2):149–166. doi: 10.1080/14787210.2023.2169131
   PubMed Web of Science ®Google Scholar
• Giuliano S, Angelini J, D’Elia D, et al. Ampicillin and ceftobiprole combination for the treatment of Enterococcus faecalis invasive infections: “the times they are a-changin”. Antibiotics. 2023;12(87):1–12. doi: 10.3390/antibiotics12050879
   Google Scholar